EBS FY 2022 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

FY 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.1B-37.0% YoY

Gross Profit

$473M42.3% margin

Operating Income

-$170M-15.2% margin

Net Income

-$212M-18.9% margin

EPS (Diluted)

$-4.47

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$150M

Stock-Based Comp.

$45M

Balance Sheet

Total Assets

$3.2B

Total Liabilities

$1.8B

Stockholders' Equity

$1.4B

Cash & Equivalents

$643M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.1B	$1.8B	-37.0%
Gross Profit	$473M	$793M	-40.4%
Operating Income	-$170M	$341M	-149.8%
Net Income	-$212M	$220M	-196.4%